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Not just another Fab: the crystal structure of a TcR–MHC–peptide
complex
Ted Jardetzky
The structure of a ternary complex formed between a
T-cell receptor, a major histocompatibility complex (MHC)
protein and a viral peptide provides new insights into the
cellular immune response. The results provide a molecular
basis for understanding the development of T cells and the
reactions leading to transplant rejection and autoimmunity.
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The development and regulation of the adaptive immune
response in complex organisms has required the evolution
of intriguing mechanisms that can dynamically respond to
and resolve problems of molecular recognition. The emer-
gence of the clonal selection theory and the demonstration
of the combinatorial diversity of antibody and T-cell
receptor (TcR) molecules have clarified how the immune
system generates an immense repertoire of antigen-recog-
nition sites. We now know that one cell type, the B cell in
the case of antibodies and the T cell for the TcR, is dedi-
cated to the production of a unique antigen-combining
site that is formed at the interface of two immunoglobulin
(Ig) variable domains [1]. The total repertoire of these
combining sites is defined by the total number of different
T or B cells that have undergone unique gene rearrange-
ments. The specificity of the antigen-combining site is
determined primarily by the sequence of hypervariable
loops at the surface of the variable Ig domains. For anti-
body molecules, the repertoire of binding sites covers a
range of antigens including small molecules, carbohy-
drates, DNA, and large protein surfaces. The problem of
fighting many pathogens is resolved by generating a nearly
infinite repertoire of receptor-binding sites by genetic
recombination.
The repertoire of mature TcRs does not cover as broad an
array of potential targets as antibodies, but is instead
restricted to the recognition of peptides that are bound to
major histocompatibility complex (MHC) glycoproteins
[2,3]. The shaping of the T cell repertoire occurs during
T cell development in the thymus, where the majority of
initial T cells are eliminated and only a small percentage
survive to make up the mature pool of cells. As Niels
Jerne pointed out over 25 years ago [4], this means that a
preselected and ‘functional population of lymphocytes is
generated before environmental antigens start to impinge
on the system’. This mechanism allows for the deletion
[5] of many T cells that react strongly against normal self
molecules (negative selection). In addition, lower affinity
(or avidity) interactions between the TcR and self MHC
molecules [5,6] are required for T cells to mature prop-
erly (positive selection), skewing the specificity of final
T cell population towards self MHC molecules. These
processes of positive and negative selection somehow
ensure enough diversity in the TcR repertoire so that
T cells can respond to almost any potential pathogen.
Here we can begin to appreciate the enigma and fascina-
tion of the T cell receptor, as it is a molecule that func-
tionally must incorporate the ability to recognize at least
two distinct targets: the first to survive T cell develop-
ment in the thymus and the second to initiate an immune
response to a specific antigen. How this duality is fos-
tered by the immune system is beginning to be under-
stood at the molecular level, with many insights provided
by the crystal structure of a TcR–MHC–peptide ternary
complex [7]. This crystal structure has provided the first
atomic resolution view of how a human TcR (A6-TcR)
recognizes a human MHC class I molecule human leuko-
cyte antigen A2 (HLA-A2) with bound antigenic peptide
(Tax peptide from the human T-cell lymphotropic virus
(HTLV-1)). General lessons for the TcR–MHC–peptide
interaction may be at hand, given the similarity of a
mouse TcR–MHC crystallographic complex that is based
on initial molecular replacement models [8]. 
The structure of the T cell receptor
The TcR is a membrane-bound protein complex com-
prised of a number of subunits. Two subunits (a and b)
are involved in recognition of the peptide–MHC complex
and additional subunits (g, d, ε, and z/h proteins) are
involved in the signal transduction mechanism. The extra-
cellular domains of the a and b chains are similar to the
Fab portion of an Ig molecule; each chain is composed of
one variable and one constant Ig domain with the two vari-
able domains (Va and Vb) forming the binding site for a
peptide–MHC complex [1]. The crystal structures of the
b chain and the variable domain of an a chain of the TcR
have been solved independently [9,10] and the structure
of the extracellular domains of an intact ab heterodimer
has been solved to high resolution [8]. This work has 
confirmed the Ig-domain structure of the TcR and uncov-
ered new variations that are unique to the TcR. The 
Va domain defines a new class of variable-domain folds,
where one of the b strands (c′′) that typically forms a sheet
with four additional b strands (cc′fg) switches over to the
other b sheet (formed by strands abde). The homodimer
of Va domains observed in crystals is very similar to the
packing arrangement observed for the ab heterodimer of
the A6-TcR, leaving the c′′ strand exposed at the TcR
surface with the potential to form interactions between
two ab heterodimers [10] or other accessory molecules.
The Ca domain is even more divergent from the canoni-
cal Ig fold [8], showing only one sheet of the typical Ig-
domain b sandwich. In the typical fold, the b sheet is
formed by strands cfg, however, in the TcR Ca domain
these strands lie too far apart to form hydrogen bonds and
strand f even forms a short helical region. This novel fold
may fill a function unique to the T-cell receptor, such as
the proposed interaction with another TcR subunit [8].
The structural variations in both the Va and Ca domains
suggest that the TcR a chain in particular may have
evolved new functional roles yet to be elucidated. 
Like antibodies, TcR sequence comparisons have revealed
regions of hypervariability (complementarity determining
regions or CDRs) that correspond to surface loops of the Ig
fold [1,11]. In the TcR, two of these loops (CDR1 and
CDR2) are encoded entirely by the germline Va and Vb
genes, while the DNA encoding a third loop (CDR3) is
only fully formed during recombination and shows greater
sequence diversity. In contrast to antibodies, there are
fewer germline encoded V regions for the TcR and these do
not undergo somatic mutation during an immune response,
leading to reduced variability in the CDR1 and CDR2
regions of the TcR. The TcR CDR3 loops, however, are
more variable than in antibodies, due to a greater number of
germline joining segments and the addition of non-tem-
plate encoded nucleotides (N nucleotides) in both the a and
b chains. Prior to the recent crystallographic studies, models
for the formation of TcR–MHC complexes have positioned
the less diverse CDR1 and CDR2 loops in contact with the
MHC molecule, with the CDR3 loops positioned to interact
with MHC-bound peptide [7]. In addition to the CDR
loops, TcRs have another region of polymorphism (HV4). 
The structure of the ternary complex
In the HLA-A2–Tax-peptide–A6-TcR crystal structure,
the TcR binds to the composite MHC–peptide molecular
surface with the TcR ab dimer axis aligned diagonally, rel-
ative to the MHC a helices (Figs 1a,b). This orientation is
similar to the one deduced from initial molecular replace-
ment models for a murine MHC–peptide–TcR complex
[8]. The CDR1 of the TcR a chain (CDR1a) covers the
N-terminal region of the Tax peptide, while CDR1 of the
b chain (CDR1b) is near the C-terminal region of the
peptide (Fig. 1c). Both CDR1 loops interact directly with
the peptide, in spite of their reduced variability relative to
the CDR3 loops (Table 1). By far the largest percentage of
the MHC–peptide surface area is buried by the b chain of
CDR3 (CDR3b), amounting to more than 50% of the total
buried surface. Over two thirds of the total buried HLA-
A2–Tax surface is actually contributed by residues from
HLA-A2 (Fig. 2a); this buried HLA-A2 surface might
provide a basal level of TcR binding affinity derived from
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Figure 1
The ternary complex of the A6-TcR–HLA-A2–Tax peptide. Ca traces of
the TcR and HLA-A2 are shown together with the molecular surface of
the Tax peptide (yellow). (a) The end view of the complex; the HLA-A2
a1 helix is on the right and the a2 helix is on the left. The a (blue) and
b (grey) chains of the TcR are labeled; the constant domain of the TcR
a chain is omitted due to poor definition in the electron-density maps
[7]. (b) Side view of the ternary complex. The HLA-A2 a1 helix is
positioned in front of the Tax peptide. (c) Close-up view of the ternary
complex in the same orientation as (b). The N and C termini of the
peptide are labeled along with Tyr5 (Y5) of the Tax peptide and the
TcR CDR3 loops. 
thymic selection that is then modulated by a specific
peptide. The authors [7] note that the majority of the
potential hydrogen bonds between the TcR and the MHC
molecule are made to residues that are conserved in many
MHC alleles (Fig. 2b). However, a substantial fraction of
the total hydrogen bonds formed by the TcR (~45%) are
directly to the Tax peptide (Fig. 2b). One of the peptide
residues (Tyr5) protrudes out of the center of the MHC-
binding site and is bound in a prominent TcR pocket
formed between the CDR3a and CDR3b loops (Fig. 1c). 
Various mechanisms have been proposed to explain signal-
ing through the TcR. Some of these rely on the aggrega-
tion or clustering of the TcR while others envisage TcR
conformational changes that could be induced upon
binding to MHC–peptide complexes. The A6-TcR does
not apparently undergo any large conformational changes
upon binding the HLA-A2–Tax complex, as judged by
comparison with other known TcR structures [7]. This
observation is consistent with models of T cell activation
based on the clustering of TcRs. However, TcR binding to
the MHC does induce a conformational adjustment of 
the Tax peptide within the HLA-A2-binding site, as well
as a small shift in one of the HLA-A2 a helices, as com-
pared with the structure of HLA-A2–Tax without bound
TcR [12]. The Tax peptide conformational change occurs
within the central amino acids, where direct contacts with
the MHC molecule are minimal. The structures of five dif-
ferent peptides bound to HLA-A2 have shown substantial
variation in the conformation in this region [12]. Peptide
conformational changes, such as those observed in the A6-
TcR–HLA-A2–Tax structure, might help explain the
effects of amino acid changes in either peptide or MHC
residues that are not directly in contact with the TcR. 
For example, Tax peptide variants that either prevent or
favor this conformational change could be expected to
influence TcR-binding affinity. However, conformational
changes of this magnitude are unlikely to be a general
feature of TcR binding, as other MHC molecules are
known to interact more directly with the central residues
of bound peptides [13]. 
In summary, the TcR interacts directly with exposed
residues of both the MHC and the peptide, laying to rest
models in which antigenic peptides are ‘detected’ indirectly
through conformational changes in the MHC, although con-
formational adjustments during ternary complex formation
are observed. The MHC–peptide surface is continuous and
peptide interactions are not limited to the TcR CDR3
loops, but include direct interactions with the CDR1 loops
as well. The same relative orientation of the TcR to the
MHC molecule has been observed in two distinct ternary
complexes, suggesting that this may be a conserved struc-
tural feature [7,8].
Table 1
Contacts of the A6-TcR hypervariable loops.
CDR loop Contacts
a1 Peptide and MHC, a1 and a2 helices
a2 MHC, a2 helix
a3 Peptide and MHC, a1 helix
b1 Peptide
b2 -
b3 Peptide and MHC, a1 and a2 helices
Figure 2
Relative contributions of peptide and MHC to the interaction with the
A6-TcR. (a) The water accessible surface area of the HLA-A2–Tax
complex that is buried by the binding of the A6-TcR. The absolute
buried surface area and the fraction of the total surface area for the Tax
peptide and HLA-A2 are indicated. (b) The number of potential
hydrogen bonds formed between the A6-TcR and HLA-A2–Tax. The
interactions between HLA-A2 and the MHC are divided into two
categories depending on whether the HLA-A2 contact residue is
conserved among many MHC proteins (grey) or whether it
corresponds to an amino acid that varies among MHC molecules
(polymorphic; white). The A6-TcR interactions with the Tax peptide
form the final category of potential hydrogen bonds (black). The
percentage of A6-TcR hydrogen bonds (20 bonds in total) for each
category is indicated, the number of hydrogen bonds is shown in
parentheses.
Hydrogen bonds formed by the A6-TcR
Tax peptide
45% (9)
Conserved MHC 
40% (8)
Polymorphic MHC
15% (3)
Surface area of HLA-A2–Tax 
buried by the TcR
HLA-A2
67% (671 Å2)
Tax peptide
33% (326 Å2)
(a)
(b)
Minireview  TcR–MHC–peptide complex Jardetzky    161
Implications for T cell development, alloreactivity and
autoimmunity
The high resolution TcR–MHC–peptide crystal structure
makes it possible to address the molecular basis for some
of the functional mysteries surrounding the TcR. As men-
tioned above, prior to encountering its eventual target
(antigenic-peptide–MHC complex), the TcR must recog-
nize a self-peptide–MHC complex in the thymus in order
for the T cell to mature properly into a functional lympho-
cyte. In addition, some mature T cells not only react with
antigenic peptides bound to self-MHC molecules, but can
also react against non-self MHC molecules in a process
known as allorecognition. For example, the 2C-TcR [8]
binds to a self-MHC molecule complexed with a self-
peptide (H2-Kb bound to the self-peptide EV-8) but also
to a complex formed between non-self MHC and a mito-
chondrial peptide (H2-Ld bound to the mitochondrial
peptide p2Ca). In other words, although thymic selection
biases the TcR repertoire towards self-MHC molecules,
this selection mechanism also retains a significant cross-
reactivity to MHC molecules that are not present in the
thymus. This cross-reactivity forms the molecular basis for
recognition events that govern transplant rejection and
may explain how a T cell response to an infectious agent
could lead to the self-reactivity observed in autoimmune
diseases [14]. 
The answer to this puzzling cross-reactivity may lie in a
conserved mode of binding between the TcR and the
MHC, as proposed by Garboczi et al. [7]. More impor-
tantly, many of the MHC surface residues that contact the
TcR are conserved among many MHC alleles (11 out of
16 residues). There are therefore potentially conserved
contacts that could form between a TcR and different
MHC molecules or the same MHC molecule complexed
with different peptides. As the MHC molecule provides
approximately two thirds of the total buried surface area
within the TcR–MHC–peptide complex (Fig. 2a), this
establishes a plausible basis for TcR cross-reactivity. In
this scenario, the peptide could provide the extra binding
energy that is necessary to trigger the T cell activation
process. Each TcR may be poised to react to some small
additional binding energy that is contributed by specific
peptide–TcR contacts. TcR affinities are typically in the
1–100 mM range and the peptide contribution to overall
binding affinity could be in the 1–5 kcalmol–1 range; this
additional binding energy would be enough to take a non-
reactive, low-affinity interaction (e.g. ~10–2–10–3 M) with
the MHC molecule, into the appropriate affinity range. 
It is clearly important to understand the kinetics of this
interaction, as the efficiency of TcR signaling is sensi-
tive to the dissociation rate of the ternary complex [15].
This aspect of TcR binding raises a number of questions.
Could the formation of a couple of hydrogen bonds
between the TcR and peptide trigger the specific recogni-
tion? How many different ways could a single TcR surface
be complemented at the level of a few good additional
non-covalent interactions? In the case of the Tax peptide,
if the tyrosine bound in the TcR CDR3 pocket (Fig. 1c) is
changed to alanine, the TcR still binds, forms crystals, and
partially activates T cells [7]. Presumably full reactivity
could be restored to this alanine mutant if the TcR–MHC
interaction was enhanced at another site: for example a
substitution at one of the polymorphic MHC positions.
This interplay between peptide sequence variability and
MHC surface polymorphism seems to be poised at the
edge of the binding energy required for T cell activation. 
It may be interesting to recall the lessons learnt from
studies of growth hormone receptor binding, which illus-
trate two relevant features of protein–protein interactions
[16,17]. Firstly, the same receptor-binding site can bind to
two different protein surfaces (growth hormone sites 1 and
2): the problem of finding a protein surface complemen-
tary to a given target site clearly has more than one solu-
tion. Secondly, a small percentage of residues (~20–30%)
in a large protein–protein interface may carry the majority
of the binding energy. In the case of TcR binding, we
may also find that different peptide–MHC combinations
can satisfy a single TcR surface with a distinct set of key
energetic interactions, in the context of a conserved set 
of TcR–MHC contacts. There are three classes of TcR
cross-reactive interactions that are of fundamental inter-
est to understand: thymic selection/antigen recognition;
allorecognition; and pathogen-triggered autoimmunity. In
each of these cases a single TcR is thought to interact
with at least two different MHC–peptide complexes. For
each TcR, we can now expect a certain fraction of its
interactions with MHC molecules to be conserved, but
this leaves a set of interactions that confers specificity on
the TcR to be explained. Are these always necessar-
ily direct interactions with peptides? Must cross-reacting
complexes have homologous peptides bound to the MHC
molecule? We now find ourselves in a position where 
we are able to further probe the structural basis for speci-
ficity and affinity in TcR–MHC recognition and eventu-
ally reveal the answers to these interesting questions.
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